Resumen
Introduction: Since 2019, cases of severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2), known as COVID-19, have emerged in Wuhan, China. This infection spread throughout the world, being recognized as a pandemic by the WHO on March 11, 2020. Most cases present mild symptoms such as low-grade fever and dry cough, however, the disease can become fatal. Patients with certain risk factors have a higher risk of infection and a worse prognosis. Patients with severe disease can rapidly progress to acute respiratory failure, acute respiratory distress syndrome, metabolic acidosis, coagulopathy, and septic shock. Objective: The purpose of this study was to evaluate the relationship between the levels of neutrophil/lymphocyte (N/L) index and the outcome of the disease (days of hospital stay, admission to intensive care and/or mortality) of patients with moderate symptoms of COVID 19 during the period of June-September 2020. Methodology: Data from 406 patients from the IGSS database was used, these patients were classified as having moderate symptoms. From them, general information, laboratory values at admission and outcome (days of hospital stay, admission to intensive care and/or mortality) were collected. Results: Of the 406 patients, 61% were diagnosed by the PCR test and 39% by antigen test. The most frequent comorbidities were: arterial hypertension, in 33% (132) of the patients, diabetes mellitus 24% (98), and chronic kidney disease 12% (49). The mean neutrophil/lymphocyte (N/L) index in the study was 9.22, higher than that reported in the literature as normal, which is 1.65. Patients transferred to ICU had an average L/N index of 14.83. Conclusion: There is a slight but significant correlation between the length of hospital stay and the neutrophil/lymphocyte index, with a p value of 0.03671, and a Spearman's r of 0.10. In addition, there is a significant difference in the distribution of N/L index in patients who were transferred to the ICU (p = 0.002878).
Citas
Chan, A. S., & Rout, A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. Journal of Clinical Medicine Research, 2020, July; 12(7): 448-453. https://doi.org/10.14740/jocmr4240 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331861/
Liu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C., Zhang, M., Tan, J., Xu, Y., Song, R., Song, M., Wang, L., Zhang, W., Han, B., Yang, L., Wang, X, Zhou, G., Zhang, T., Li, B., Wang, Y., Chen, Z., Wang, X. Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage. Journal Translational Med. 2020, May; 18(1): 206. https://doi.org/10.1101/2020.02.10.20021584 https://doi.org/10.1186/s12967-020-02374-0 https://www.medrxiv.org/content/10.1101/2020.02.10.20021584v1
Forget, P., Khalifa, C., Defour, J-P., Latinne, D., Van Pel, M. V., & De Kock, M. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Research Notes, 2017, Jan.; 10(1): 12. https://doi.org/10.1186/s13104-016-2335-5 https://pubmed.ncbi.nlm.nih.gov/28057051/
Liu, Y., Du, X., Chen, J., Jin, Y., Peng, L., Wang, H.H.X., Lou, M., Chen, L., Zhao, Y. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection, 2020, July; 81(1): e6-e12. https://doi.org/10.1016/j.jinf.2020.04.002 https://pubmed.ncbi.nlm.nih.gov/32283162/
Ciccullo, A., Borghetti, A., Dal Verme, L. Z., Tosoni, A., Lombardi, F., Garcovich, M., Biscetti, F., Montalto, M., Cauda, R., Di Giambenedetto, S. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: A report from the Italian front line. International Journal of Antimicrobial Agents, 2020, Aug.; 56(2): 106017. https://doi.org/10.1016/j.ijantimicag.2020.106017 https://pubmed.ncbi.nlm.nih.gov/32437920/
Tatum, D., Taghavi, S., Houghton, A., Stover, J., Toraih, E., & Duchesne, J. Neutrophil-to-Lymphocyte Ratio and Outcomes in Louisiana COVID-19 Patients. Shock, 54(5), 652-658. https://doi.org/10.1097/SHK.0000000000001585 https://pubmed.ncbi.nlm.nih.gov/32554992/#:~:text=Mortality%20was%2018.4%25.,P%20%3D%200.002%2C%20respectively).
Interleukin-6 (IL-6), Serum, CBC (includes Differential and Platelets), D-Dimer, Quantitative - Find Lab Tests Online. 2021. https://www.findlabtest.com/lab-test/search?q=qt34473+qt6399+qt8659
Copyright
License
Copyright (c) 2021 Nataly Alejandra Rueda Lara, Andrés Antonio Sánchez Salazar y Luis Arturo Rodríguez Cifuentes
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License 4.0 (CC BY-NC_SA 4.0) that indicates: a) It is allowed that others share the work, with an acknowledgement of the work's authorship and initial publication in this journal, b) The work may not be used for commercial purposes, c) If it's remixed, transformed, or built upon the material, one must distribute the contributions under the same license as the original
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository, website or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
